Presentations

ICARE AD-US: Design of a Prospective, Single-arm, Multicenter, Noninterventional Real-world Study of Aducanumab in United States

Reduction in Biomarkers of Alzheimer’s Disease Pathophysiology Following Treatment with Aducanumab Were Associated with Slowing Clinical Decline

Subgroup Analyses of the Amyloid PET Substudies from EMERGE and ENGAGE, Phase 3 Clinical Trials Evaluating Aducanumab in Patients with Early Alzheimer’s Disease

Considerations for the Real-World Management of ARIA from the Aducanumab Phase 3 Studies EMERGE and ENGAGE

Item-level Analysis of Clinical Measures in Patients with Early Symptomatic Alzheimer’s Disease Following Treatment with High-Dose Aducanumab in the Phase 3 Study EMERGE

Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase 1b Study of Lumbar Intrathecal Bolus Administrations of Antisense Oligonucleotide (ISIS 814907; BIIB080) Targeting Tau mRNA in Patients with Mild Alzheimer’s Disease

Aducanumab EMBARK study design poster at AAN 2021

Aducanumab EMBARK study design audio presentation at AAN 2021

Evaluation of aducanumab safety in early Alzheimer’s disease at AD/PD

Evaluation of aducanumab efficacy in early Alzheimer’s disease at AD/PD

Cerebrospinal Fluid Biomarker Concordance with Amyloid PET in EMERGE and ENGAGE at AD/PD

Aducanumab data review with Global Alzheimer's Platform Foundation

Aducanumab data review and Q&A with Alzheimer's Disease International

Aducanumab EMBARK study design at CTAD 2020

Aducanumab Phase 3 Topline Results at the AAN 2020 Science Highlights (encore virtual presentation)

Aducanumab Phase 3 Topline Results at the 23rd Chinese National Conference of Neurology (encore virtual presentation)

A Biogen Perspective on Drug Development for Neurological Diseases: The Example of Alzheimer’s Disease

Aducanumab Phase 3 Topline Results at AAIC (encore virtual presentation)

Aducanumab Phase 3 Topline Results at AAN (encore virtual presentation)

Aducanumab Phase 3 Topline Results at AAT-AD/PD (encore presentation)

Aducanumab Phase 3 Topline Results at CTAD

Safety, PK, PD, and Exploratory Efficacy in Single and Multiple Dose Study of a SOD1 Antisense Oligonucleotide (BIIB067) Administered to Participants With ALS

CTAD Oral Presentation: Aducanumab Titration Dosing Regimen: 36-Month Analyses from PRIME, a Phase 1b Study in Patients with Early Alzheimer’s Disease

CTAD Keynote: What Have We Learned from Aducanumab?

Cumulative Aducanumab Safety Data from PRIME: A Randomized, Double-blind, Placebo-controlled, Phase 1b Study

Aducanumab 48-Month Analyses from PRIME, a Phase 1b Study in Patients with Early Alzheimer’s Disease

24-Month Analysis of APOE ε4 Carriers in PRIME, a Randomized Phase 1B Study of the Anti-Amyloid Beta Monoclonal Antibody Aducanumab

24-Month Analysis of Change From Baseline In Clinical Dementia Rating Scale Cognitive and Functional Domains in PRIME, A Randomized Phase 1b Study of the Anti-Amyloid Beta Monoclonal Antibody Aducanumab

Aducanumab Titration Dosing Regimen: 24-Month Interim Analysis from PRIME, a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study in Patients With Prodromal or Mild Alzheimer’s Disease

Aducanumab 36-Month Data From PRIME: A Randomized, Double-Blind, Placebo-Controlled Phase 1b Study in Patients With Prodromal or Mild Alzheimer’s Disease

The Importance of Early Identification and Treatment of Alzheimer’s Disease

NUSINERSEN CHERISH Final Results (Poster & Presentation) Ph3 AAN 2017

NUSINERSEN NURTURE Interim Results (Presentation) Ph3 AAN 2017

NUSINERSEN ENDEAR Final Results (Presentation) Ph3 AAN 2017